Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
Status:
Unknown status
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
It is hypothesize that, because dapagliflozin will reverse the metabolic defects responsible
for the development of prediabetes (i.e. insulin resistance and beta cell dysfunction) and
progression from prediabetes to T2DM (beta cell dysfunction) and will cause weight loss, it
will markedly reduce the progression from prediabetes to T2DM and reverse glucose tolerance
to NGT in patients with prediabetes experiencing acute myocardial infarction. Further, it is
hypothesized that the hemodynamic actions of dapagliflzoin will exert cardiovascular benefit
in subjects with prediabetes and acute MI by reducing cardiac remodeling, preserve LV
function and decrease the risk of development of heart failure and hospitalization for heart
failure.
Hence, aim to examine the impact of SGLT2 inhibitor on T2DM and cardiovascular risk in
patients with prediabetes and cardiovascular disease.
The primary objective of the study is to examine the effect of dapagliflozin (10 mg) on the
progression from prediabetes to T2DM in patients with prediabetes who experience acute
myocardial infarction (MI). A secondary objective is to examine the effect of dapagliflozin
on a composite of CV outcome including incidence and hospitalization for heart failure in
patients with prediabetes with acute MI. Other secondary outcome is the change from baseline
to end of study in LD systolic and diastolic function.